6.
Mingrone G, Castagneto-Gissey L, Bornstein S
. New Horizons: Emerging Antidiabetic Medications. J Clin Endocrinol Metab. 2022; 107(12):e4333-e4340.
DOI: 10.1210/clinem/dgac499.
View
7.
Muramoto A, Matsushita M, Kato A, Yamamoto N, Koike G, Nakamura M
. Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract. 2014; 8(5):e466-75.
DOI: 10.1016/j.orcp.2013.10.003.
View
8.
Yamaguchi T, Tani M, Kasama K, Naitoh T, Oshiro T, Inoue K
. Reference Values for Weight Loss During 1 Year After Sleeve Gastrectomy: a Multicenter Retrospective Study in Japan. Obes Surg. 2022; 32(8):2672-2681.
DOI: 10.1007/s11695-022-06125-6.
View
9.
Kimura Y, Fujishima Y, Nishizawa H, Saito T, Miyazaki Y, Shirahase K
. Changes in Eating Behaviors and Their Associations with Weight Loss in Japanese Patients Who Underwent Laparoscopic Sleeve Gastrectomy. Nutrients. 2023; 15(2).
PMC: 9866351.
DOI: 10.3390/nu15020353.
View
10.
Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T
. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007; 102(12):2708-15.
DOI: 10.1111/j.1572-0241.2007.01526.x.
View
11.
Yamakage H, Jo T, Tanaka M, Kato S, Hasegawa K, Masuda I
. Five percent weight loss is a significant 1-year predictor and an optimal 5-year cut-off for reducing the number of obesity-related cardiovascular disease risk components: the Japan Obesity and Metabolic Syndrome Study. Front Endocrinol (Lausanne). 2024; 15:1343153.
PMC: 11005029.
DOI: 10.3389/fendo.2024.1343153.
View
12.
Saito I
. Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. Circ J. 2012; 76(5):1066-73.
DOI: 10.1253/circj.cj-11-1519.
View
13.
Yoshikawa K, Kishi T, Takamori A, Kitajima A, Goto T, Nakayama S
. Lower body bone fractures have high mortality rates and poor prognosis in the patients with hemodialysis. Ther Apher Dial. 2024; 28(5):690-696.
DOI: 10.1111/1744-9987.14139.
View
14.
Ogawa W, Hirota Y, Miyazaki S, Nakamura T, Ogawa Y, Shimomura I
. Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. Endocr J. 2023; 71(3):223-231.
DOI: 10.1507/endocrj.EJ23-0593.
View
15.
Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K
. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012; 47(5):586-95.
DOI: 10.1007/s00535-012-0533-z.
View
16.
Oza N, Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Horie H
. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol. 2009; 44(12):1203-8.
DOI: 10.1007/s00535-009-0115-x.
View
17.
. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421.
View
18.
Park S, Shimokawa I
. Influence of Adipokines on Metabolic Dysfunction and Aging. Biomedicines. 2024; 12(4).
PMC: 11048512.
DOI: 10.3390/biomedicines12040873.
View
19.
Nakayama S, Yamanouchi K, Takamori A, Goto T, Shimada F, Imamura T
. Gastrointestinal bleeding among 151 patients undergoing maintenance hemodialysis for end-stage renal failure: A 5-year follow-up study. Medicine (Baltimore). 2024; 103(7):e37274.
PMC: 10869079.
DOI: 10.1097/MD.0000000000037274.
View
20.
Godo S, Suda A, Takahashi J, Yasuda S, Shimokawa H
. Coronary Microvascular Dysfunction. Arterioscler Thromb Vasc Biol. 2021; 41(5):1625-1637.
DOI: 10.1161/ATVBAHA.121.316025.
View